Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

Core Insights - Kura Oncology announced that two abstracts featuring clinical data from the KOMET-007 trial of ziftomenib have been accepted for presentation at the ASH Annual Meeting in December 2024 [1][2] Group 1: Clinical Trial Details - KOMET-007 is a multicenter Phase 1 trial evaluating ziftomenib in combination with standard treatments for patients with NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML) [2] - The Phase 1a dose-escalation portion of the study has shown that all four cohorts have cleared the highest dose and advanced to the Phase 1b expansion study at 600 mg [2] Group 2: Safety and Efficacy - Clinical data suggests ziftomenib has a potential best-in-class safety and tolerability profile, demonstrating robust activity in combination with standard care [3] - In the relapsed/refractory AML setting, ziftomenib combined with venetoclax/azacitidine has shown encouraging activity, with no dose-limiting toxicities or QTc prolongation reported [3] - In newly diagnosed adverse risk AML patients, 100% of NPM1-m patients and 84% of KMT2A-r patients remained on study approximately one year after the study start [3] Group 3: Upcoming Presentations - The oral presentation on ziftomenib combined with 7+3 will take place on December 7, 2024, at the San Diego Convention Center [4] - The poster presentation on ziftomenib combined with ven/aza is scheduled for December 8, 2024, at the same venue [4] Group 4: Company Overview - Kura Oncology is focused on precision medicines for cancer treatment, with ziftomenib being a key candidate targeting the menin-KMT2A interaction [5] - The company has received Breakthrough Therapy Designation for ziftomenib in treating relapsed/refractory NPM1-m AML and is conducting multiple clinical trials to evaluate its efficacy [5]